These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 15999217

  • 41. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia.
    Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z, 037 STUDY GROUP.
    Urology; 2006 Apr; 67(4):731-6; discussion 736. PubMed ID: 16618562
    [Abstract] [Full Text] [Related]

  • 42. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Khullar V, Hill S, Laval KU, Schiøtz HA, Jonas U, Versi E.
    Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Does concomitant diabetes affect treatment responses in overactive bladder patients?
    Schneider T, Marschall-Kehrel D, Hanisch JU, Michel MC.
    Int J Clin Pract; 2013 Nov; 67(11):1138-43. PubMed ID: 24165427
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Assessment of cognitive function of the elderly population: effects of darifenacin.
    Lipton RB, Kolodner K, Wesnes K.
    J Urol; 2005 Feb; 173(2):493-8. PubMed ID: 15643227
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
    Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, Dorrepaal C, Martin N.
    Eur Urol; 2013 Feb; 63(2):296-305. PubMed ID: 23195283
    [Abstract] [Full Text] [Related]

  • 57. Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve.
    Iijima K, De Wachter S, Wyndaele JJ.
    Eur Urol; 2007 Sep; 52(3):842-7. PubMed ID: 17360104
    [Abstract] [Full Text] [Related]

  • 58. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J.
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms.
    Zinner NR, Dmochowski RR, Staskin DR, Siami PF, Sand PK, Oefelein MG.
    Neurourol Urodyn; 2011 Sep; 30(7):1214-9. PubMed ID: 21462240
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.